BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8894600)

  • 1. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
    Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
    Taniguchi H; Yazaki N; Endo T; Nagasaki M
    Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
    Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
    J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of two cholecystokinin-receptor antagonists, loxiglumide and L-364,718, on the pancreatic secretory response to intraduodenal tryptophan in dogs.
    Niebergall-Roth E; Teyssen S; Wetzel D; Hartel M; Beglinger C; Riepl RL; Singer MV
    Scand J Gastroenterol; 1996 Jul; 31(7):723-32. PubMed ID: 8819225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
    Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
    Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
    Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M
    Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini.
    Akiyama T; Otsuki M
    Pancreas; 1994 May; 9(3):324-31. PubMed ID: 8022754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
    Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M
    Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
    Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cholecystokinin receptor antagonist, loxiglumide, stimulates biliary secretion in conscious rats.
    Watanabe N; Otsuki M
    Eur J Pharmacol; 1994 Nov; 264(3):331-6. PubMed ID: 7698173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a novel cholecystokinin receptor antagonist, FK480, administered intraduodenally, on pancreatic secretion in rats.
    Moriyoshi Y; Shiratori K; Takeuchi T; Watanabe S
    Pancreas; 1995 Apr; 10(3):295-300. PubMed ID: 7542771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camostate- and caerulein-induced delay of gastric emptying in the rat: effect of CCK receptor antagonists.
    Varga G; Scarpignato C
    Eur J Pharmacol; 1996 Jun; 306(1-3):153-9. PubMed ID: 8813627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
    Louie DS; Liang JP; Owyang C
    Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin antagonistic activities of loxiglumide.
    Wakatsuki K; Saito T; Saeki M; Ninomiya K; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1997 Oct; 47(10):1130-3. PubMed ID: 9368707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
    Nakano S; Kihara Y; Otsuki M
    Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
    Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticholecystokinin activities of loxiglumide.
    Setnikar I; Bani M; Cereda R; Chisté R; Makovec F; Pacini MA; Revel L
    Arzneimittelforschung; 1987 Oct; 37(10):1168-71. PubMed ID: 3435589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion.
    Tanikawa M; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Kodaira T; Hamaoka T
    Arzneimittelforschung; 1993 Jan; 43(1):35-9. PubMed ID: 8447844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.